Literature DB >> 11001382

Does p53 status influence tumor response to anticancer therapies?

K F Pirollo1, K B Bouker, E H Chang.   

Abstract

Abnormalities in the tumor suppressor gene p53 have been identified in over 60% of human cancers. Since it plays such a pivotal role in cell growth regulation and apoptosis, the status of the p53 gene has been proposed as one of the major determinants of a tumor's response to anticancer therapies. In this review we examine the relationship between functional p53 and sensitivity/resistance to both chemotherapy and radiotherapy, and discuss the potential use of some of the current gene therapy approaches to restore functional p53 to tumors as a means of modulating the effects of radiation and chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11001382     DOI： 10.1097/00001813-200007000-00002

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN： 0959-4973            Impact factor:   2.248


  11 in total

1.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Authors:  T Watanabe; T T Wu; P J Catalano; T Ueki; R Satriano; D G Haller; A B Benson; S R Hamilton
Journal:  N Engl J Med       Date:  2001-04-19       Impact factor: 91.245

Review 2.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

3.  Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells.

Authors:  Jun Yang; Yun Yang; Li Tian; Xi-Feng Sheng; Fei Liu; Jian-Guo Cao
Journal:  World J Gastroenterol       Date:  2011-10-14       Impact factor: 5.742

4.  Glucose deprivation increases nuclear DNA repair protein Ku and resistance to radiation induced oxidative stress in human cancer cells.

Authors:  Jie Li; Roashan Ayene; Kathleen M Ward; Eswarkumar Dayanandam; Iraimoudi S Ayene
Journal:  Cell Biochem Funct       Date:  2009-03       Impact factor: 3.685

5.  ATR mediates cisplatin resistance in a p53 genotype-specific manner.

Authors:  N Sangster-Guity; B H Conrad; N Papadopoulos; F Bunz
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

6.  The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone.

Authors:  Yu-Ping Yang; Hsien-Shou Kuo; Hsin-Da Tsai; Yi-Chen Peng; Yuh-Ling Lin
Journal:  Breast Cancer Res       Date:  2004-11-04       Impact factor: 6.466

7.  Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein.

Authors:  S Menéndez; M Higgins; R G Berkson; C Edling; D P Lane; S Laín
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

8.  Caspase Activation and Aberrant Cell Growth in a p53(+/+) Cell Line from a Li-Fraumeni Syndrome Family.

Authors:  Zaki A Sherif
Journal:  Genet Res Int       Date:  2015-03-18

9.  A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.

Authors:  Ellen Siebring-van Olst; Maxime Blijlevens; Renee X de Menezes; Ida H van der Meulen-Muileman; Egbert F Smit; Victor W van Beusechem
Journal:  Mol Oncol       Date:  2017-04-11       Impact factor: 6.603

10.  Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.

Authors:  Huiyan Ma; Yani Lu; Kathleen E Malone; Polly A Marchbanks; Dennis M Deapen; Robert Spirtas; Ronald T Burkman; Brian L Strom; Jill A McDonald; Suzanne G Folger; Michael S Simon; Jane Sullivan-Halley; Michael F Press; Leslie Bernstein
Journal:  BMC Cancer       Date:  2013-05-04       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.